The term “coronavirus” and the disease COVID-19 have become ubiquitous in daily communications across the globe. While many initially asked why testing for the coronavirus that causes COVID-19 was slow to roll out, and why tests in many countries were inaccurate, one question no one seems to be asking is why the pursuit of a vaccine is going so slow. Indeed, by all reports from both public and private sectors, the first viable vaccines are months, if not weeks away.

“All of what is being accomplished today is the result of years of innovation,” said USPTO Director Andrei Iancu in a recent interview with IPWatchdog.com. “It is important not to lose track of that.” Indeed, the fact that multiple companies are racing toward a vaccine in unprecedented time frames is precise because of the vast amounts of research and development that have taken place in the years leading up to the current COVID-19 pandemic.

Amidst this backdrop, join Gene Quinn, patent attorney and leading commentator on patent law and innovation policy, Gene will host a wide-ranging conversation on the topic of COVID-19 and the race toward a coronavirus vaccine. In addition to discussing the science and FDA processes involved, we discuss intellectual property rights and more. Joining Gene will be immunization expert Dr. Jonathan Temte, a Professor at the Wisconsin School of Medicine who also serves as a member of the CDC’s Board of Scientific Counselors, and Melissa Brand, Assistant General Counsel for Intellectual Property at the Biotechnology Innovation Organization, and Erika Lietzan,  Associate Professor of Law at the University of Missouri School of Law.

This webinar is sponsored by Morningside IP.